Are you ready to face MedTech challenges, such as a changing regulatory environment and an AI-driven landscape?
Join BioBridges as we discuss these challenges with our panelists. You’ll learn:
đź“Ť Which Regulatory changes are coming in 2025, and how to plan for them?
đź“Ť How to navigate challenging times in the #MedTech space in a world of uncertainty.
đź“Ť Strategies on how to get products from concept to commercialization
Our expert panelists will foster an innovative conversation with unique perspectives on the future of medical technology.
About Our Panelists
Paul O’Connor
Medical Device Development
Paul O’Connor is an engineering leader in medical devices. With experience in product design, R&D, and business management, his innovative mindset is looking ahead at the future medical technology landscape. O’Connor has an MS in Management from Lesley University and a BS in Mechanical Engineering from Northeastern University.
Sally Bowden
Partner & Co-Founder, The P3 Acceleration Group
Sally Bowden is a strategic and innovative builder of best-in-class life sciences and diagnostic organizations. She has over 25 years of experience in quality, regulatory, and operations fields in medical devices and diagnostics. Bowden’s professional experience consists of impressive titles- VP Corporate Quality and Competitive Excellence, VP of Regulatory Compliance and Quality, Head of Regulatory Affairs, VP of Quality and Regulatory Affairs, and CEO.
Eric Distad
Founder & Lead Consultant, Anchor Point Clinical Consulting
Eric Distad is a clinical operations expert with 25+ years of experience. He specializes in the development and execution of clinical programs and is an expert in resource modeling and site selection, publication strategies, regulatory strategy review, KOL/SAB development, and investigator meetings. His therapeutic expertise ranges from neurology, cardiology, degenerative spine disorders, and diabetes.
BioBridges has been a trusted life science partner for more than 20 years. With the launch of its new MedTech division, the company is reinforcing its dedication to supporting the development of cutting-edge medical technologies that improve patient care
